Clinical Trials Logo

Hyperphagia clinical trials

View clinical trials related to Hyperphagia.

Filter by:

NCT ID: NCT04768803 Recruiting - Epilepsy Clinical Trials

Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity

HOGRID
Start date: June 10, 2021
Phase:
Study type: Observational [Patient Registry]

A significantly higher proportion of patients with rare diseases (RD) with intellectual disability (ID), present hyperphagia, overweight or obesity, compared to the general population. Prader-Willi syndrome is the only genetic obesity identified to date associated with hyperghrelinemia, while ghrelin levels are lower than in controls in other situations of obesity. The aim of the study is to find out whether the levels of ghrelin, which are abnormally high in PWS throughout life, are also high in these RD when people have hyperphagia and/or overweight.

NCT ID: NCT03554031 Recruiting - Clinical trials for Prader-Willi Syndrome

A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome

Start date: April 14, 2018
Phase: Phase 3
Study type: Interventional

To evaluate the effectiveness of rhGH (Recombinant human growth hormone) injection for improving motor development in patients with PWS.

NCT ID: NCT03197662 Recruiting - Clinical trials for Prader-Willi Syndrome

Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome

Start date: April 11, 2018
Phase: Phase 2
Study type: Interventional

This study is a phase 2 randomized double blind 8-week treatment trial of intranasal OXT vs. placebo in 50 subjects aged 5 to 17 years with PWS in order to assess IN-OXT's affect on measurements of (1) eating behaviors (2) repetitive behaviors (3) weight and body composition (4) quality of life (5) salivary OXT and hormone levels (including ghrelin, pancreatic polypeptide, peptide YY, GLP-1, insulin, glucagon, testosterone, and estrogen). If superior to placebo, this data will add to the current knowledge that OXT is an effective treatment for hyperphagia as well as other symptoms of PWS. Funding Source- FDA OOPD

NCT ID: NCT02758262 Recruiting - Hyperphagia Clinical Trials

Effects of Noninvasive Brain Stimulation on Brain Activity and Appetite

Start date: April 2016
Phase: N/A
Study type: Interventional

The goal of this project is to identify brain mechanisms by which Noninvasive brain stimulation (NIBS) could decrease hyperphagia. The investigators will synchronously deliver NIBS and measure brain activity in a randomized, crossover, sham-controlled, fully blind study. This work will reveal brain mechanisms to reduce hyperphagia and may contribute to new therapeutic avenues to treat this eating disorder.